(FREE BEACON) – In New York, racial minorities are automatically eligible for scarce COVID-19 therapeutics, regardless of age or underlying conditions. In Utah, "Latinx ethnicity" counts for more points than "congestive heart failure" in a patient’s "COVID-19 risk score"—the state’s framework for allocating monoclonal antibodies. And in Minnesota, health officials have devised their own "ethical framework" that prioritizes black 18-year-olds over white 64-year-olds—even though the latter are at much higher risk of severe disease.
These schemes have sparked widespread condemnation of the state governments implementing them. But the idea to use race to determine drug eligibility wasn’t hatched in local health departments; it came directly from the federal Food and Drug Administration.
Advertisement - story continues below
When the FDA issued its emergency use authorizations for monoclonal antibodies and oral antivirals, it authorized them only for "high risk" patients—and issued guidance on what factors put patients at risk. One of those factors was race.